Stockholm 3 Validation Study
Research type
Research Study
Full title
Stockholm 3 Test Validation Study in Prostate Cancer
IRAS ID
235942
Contact name
Nick Burns-Cox
Contact email
Sponsor organisation
Taunton and Somerset NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Prostate cancer is a common disease and the fourth most common cause of cancer death in men in the UK with 11,300 men dying in 2014. However only about 30% of prostate cancer maybe aggressive and we need tests that can distinguish between the aggressive prostate cancers and the low risk which may not benefit from treatment.\nA blood test measuring Prostate Specific Antigen (PSA ) is currently the most widespread test for patients if prostate cancer is a concern. PSA testing however is inaccurate the majority of men with an abnormal test result will not have prostate cancer and many men with prostate cancer have a normal PSA test result. \nThe Stockholm 3 test has already been shown in studies to be more accurate than PSA testing not only identifying patients with more aggressive prostate cancer but also potentially reducing the number of men who require a prostate biopsy.\nThis study will further evaluate the effectiveness of the Stockholm 3 test in men in the UK being investigated for possible prostate cancer usually because of an abnormal PSA test result. The study will be in NHS hospitals and will recruit 60 men over a 12 month period. All men will undergo standard investigations but if recruited to the study will answer 4 questions about their health and give one extra blood sample. This will not delay their routine investigations.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
18/SC/0221
Date of REC Opinion
30 Apr 2018
REC opinion
Favourable Opinion